FRANKFURT (dpa-AFX) - A warning of uncertainty around the company's 2022 targets weighed on shares of Dermapharm on Wednesday. The previous evening, shortly after the stock market closed, Bloomberg news agency quoted from a presentation that said the outlook so far was subject to increasing risks due to the development of the Corona pandemic and the Ukraine crisis.

Traders saw this as a weighing factor on Wednesday for the papers of the pharmaceutical company, which is one of Biontech's partners in the production of the Corona vaccine. After reaching a high since the beginning of December the previous day, Dermapharm shares now went downhill. The price losses widened to 3.6 percent over the course of the day, most recently at 39.04 euros. With the 50- and 100-day lines, the shares fell below two relevant medium-term chart indicators.

One stockbroker pointed out that the company had previously indicated that it would probably only achieve the lower end of its target ranges in terms of sales and operating profit (Ebitda). However, he believes that on this basis only a cautious outlook for 2023 is likely to follow. Another stockbroker then fears further declines in Corona-related sales./tih/jha/